Status:
COMPLETED
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
Lead Sponsor:
Bayer
Conditions:
Pelvic Inflammatory Disease
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (PID)
Eligibility Criteria
Inclusion
- Diagnosis of uncomplicated PID based on the absence of pelvic or tubo-ovarian abscess at pelvic ultrasound and/or laparoscopic examination.
Exclusion
- Subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT00453349
Start Date
January 1 2007
End Date
May 1 2008
Last Update
September 8 2014
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenyang, Liaoning, China, 110004
2
Chengdu, Sichuan, China, 610041
3
Beijing, China, 100034
4
Beijing, China, 100083